Overview

A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

Status:
Unknown status

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the antitumor activity of a combination of Imatinib mesylate and Gemcitabine in patients with unresectable malignant mesothelioma expressing either PDGFR-beta or C-kit

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Italiano MEsotelioma

Treatments:

Gemcitabine
Imatinib Mesylate